Evidence map›Paper›PMID 40932460›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease.

Henna Butt, Neal Jeffries, Triscia Martin, Valeria De Giorgi, Alison Zamora, John F Tisdale, Matthew M Hsieh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease.Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Henna ButtCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-1074-8480
Neal JeffriesOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Triscia MartinCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Valeria De GiorgiDepartment of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Alison ZamoraDepartment of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
John F TisdaleCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Matthew M HsiehCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-3706-6615

Funding

Nonmyeloablative allogeneic PBSC in globin disordersZ01HL006007 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI TISDALE, JOHN · 2008 to 2008
$384k
Intramural NIH HHS Z01 HL006007Intramural NIH HHS Z99 HL999999NHLBI NIH HHS HL006007
6 · The paper itself

Abstract

backgroundSickle cell disease (SCD) can be cured by hematopoietic cell transplantation (HCT), but patients face increased risk of hepatitis B virus (HBV) reactivation due to immunosuppression. Understanding hepatitis B surface antibody (anti-HBs) kinetics is essential for optimizing HBV revaccination and posttransplant care.

methodsThis post hoc analysis examined HBV immunity, reactivation, and revaccination response in 71 SCD patients who underwent HCT at the National Heart, Lung, and Blood Institute (2008-2021) using alemtuzumab and low-dose total body irradiation.

resultsAt baseline, 55% showed HBV immunity (anti-HBs ≥ 12 mIU/mL). Most patients responded to revaccination regardless of baseline immunity. Post-HCT revaccination was given to 93%, with 89% completing full series (Heplisav-B or Engerix-B). Vaccinated patients had a 67.5% chance of increased anti-HBs titers between Years 1 and 2, though no significant difference was seen compared to unvaccinated patients (p = 0.12). No HBV reactivation occurred; two patients with baseline HBcAb and HBsAg positivity showed decreasing HBV DNA levels.

conclusionsResults indicate that HBV immunity can decline post-HCT, but most patients remain immune, and revaccination is effective. However, some non-responders-especially those treated with IVIG, rituximab, or prolonged immunosuppression-need further study. Prospective research is needed to optimize revaccination timing and immune monitoring in this high-risk group.

Indexed as

Anemia, Sickle CellHematopoietic Stem Cell TransplantationHepatitis BHepatitis B VaccinesHepatitis B virusImmunization, SecondaryVirus ActivationAdolescentAdultAlemtuzumabFemaleHepatitis B AntibodiesHepatitis B Surface AntigensHumansImmunosuppressive AgentsMaleAlemtuzumabHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesImmunosuppressive AgentsHCThepatitis Breactivationsickle cell diseasevaccination

Identifiers

PMID40932460
PMCPMC12720196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.